GeoVax Secures Patent for Innovative Malaria Vaccine Design
June 25th, 2025 12:00 PM
By: Advos Staff Reporter
GeoVax Labs, Inc. has been granted a U.S. patent for a novel vaccine construct aimed at preventing malaria, marking a significant advancement in the fight against the disease and enhancing global health security.
GeoVax Labs, Inc., a biotechnology firm specializing in vaccine development, has announced the issuance of a U.S. patent for a groundbreaking vaccine construct designed to prevent malaria. The patent, U.S. Patent No. 12,329,808, covers a recombinant Modified Vaccinia Ankara (MVA) viral vector that expresses immunogenic proteins from Plasmodium falciparum, the parasite responsible for malaria. This innovative approach utilizes virus-like particles (VLPs) to enhance vaccine potency, aiming to induce both humoral and T-cell responses.
David Dodd, President and CEO of GeoVax, emphasized the importance of this patent in advancing vaccines for high-consequence pathogens, highlighting the company's commitment to global health security. With malaria causing over 600,000 deaths annually, primarily in sub-Saharan Africa, this development represents a critical step forward in combating the disease.
GeoVax's portfolio now includes over 135 granted or pending patent applications across various fields, including oncology and infectious diseases. This latest patent underscores the company's strategic focus on addressing both endemic and emerging health threats through its multi-antigenic platform strategy.
Source Statement
This news article relied primarily on a press release disributed by NewMediaWire. You can read the source press release here,
